Skin Cancer Treatment Options

Start Here: Skin Cancer Is Not One Disease

“Skin cancer” describes a family of diseases, not one interchangeable condition.

• Basal cell carcinoma (BCC) arises from cells related to the basal layer of the epidermis. It is usually highly curable and rarely spreads, but it can grow deeply, recur, and damage important structures.
• Cutaneous squamous cell carcinoma (cSCC) arises from keratinocytes. Most are cured locally, but higher-risk tumors can spread to lymph nodes or distant organs.
• Melanoma arises from melanocytes, the pigment-producing cells. Treatment depends heavily on depth, ulceration, lymph nodes, and stage.
• Rare skin cancers include dermatofibrosarcoma protuberans, Merkel cell carcinoma, extramammary Paget disease, adnexal carcinomas, and other tumors with diagnosis-specific rules.

The same treatment cannot be declared “best” without naming the cancer and the clinical problem. A small superficial BCC on the trunk is not the same disease decision as a recurrent infiltrative BCC on the nose. SCC in situ is not the same problem as a deeply invasive SCC with nerve symptoms. Melanoma in situ is not the same problem as an ulcerated invasive melanoma with nodal disease.^1–6

The correct question is not merely, “What treats skin cancer?” It is, “Which treatment gives this cancer the strongest control with the least unnecessary harm?”

Five Ideas That Make the Treatment Plan Understandable

1. Diagnosis

The pathology report identifies the tumor family and features that may change treatment. A partial biopsy answers what was sampled; it may not reveal every growth pattern or the full edge of a heterogeneous tumor.^1,4,32,33

2. In situ versus invasive

In situ means abnormal cells remain within the epidermis. Invasive means tumor cells have crossed into deeper tissue. This distinction can change whether topical treatment, curettage, surgery, nodal evaluation, or systemic therapy is appropriate.

3. Risk versus stage

Risk estimates how likely a tumor is to recur, spread, or cause local harm. Stage estimates how far the disease has extended. They overlap, but they are not the same.^1–3

4. Margin

A surgical margin is the edge around and beneath the removed tumor. Different treatments provide different levels of information about that edge.

5. Local versus systemic treatment

Local treatment addresses the primary site. Systemic treatment circulates through the body and is used when the disease or recurrence risk extends beyond one local operation.

Start a treatment comparison with the exact diagnosis, risk, site, treatment goal, and how clearance will be assessed.

Treatment Starts With the Tumor

Diagnosis, tumor risk, anatomy, overall health, and patient goals can appropriately lead to different treatments. Before choosing a procedure, identify:

• the exact diagnosis;
• whether it is in situ or invasive;
• location, size, borders, depth, and prior treatment;
• biopsy subtype, differentiation, nerve or vascular involvement, and sampling limits;
• immune status and relevant medical conditions;
• whether lymph-node examination, imaging, or staging is needed;
• whether a major repair will follow; and
• what outcome matters most to the patient.^1–6

How the Main Treatments Differ

Why Margin Assessment Matters

Cancer often extends beyond what the eye can see. Margin assessment asks whether tumor remains at the edge of removed tissue.

Standard excision

The surgeon removes the visible tumor plus a planned rim of normal-appearing tissue. The specimen is oriented and processed after removal. Pathologists generally examine representative vertical sections through the specimen.^7,8

Mohs surgery

The surgeon removes a thin layer, maps exactly where it came from, and examines the peripheral and deep surgical margin as a mapped en-face surface. If cancer remains, another layer is taken only from the positive location.^7,8

What this means for a patient

Margin information matters most when the cancer's hidden edge is unpredictable, normal tissue is valuable, recurrence would be costly, or reconstruction should not begin until the cancer-free wound is known.

Mohs Surgery

Mohs is the strongest local treatment for the majority of high-risk head-and-neck basal and squamous cell carcinomas. It combines complete mapped margin assessment with deliberate tissue preservation. That combination improves the cancer operation and the reconstruction that follows.^1,2,7–9

Mohs becomes especially valuable when a tumor is:

• recurrent;
• poorly defined;
• aggressive or mixed on biopsy;
• located on the nose, eyelid, ear, lip, hand, foot, genital area, or another tissue-sensitive site;
• a higher-risk cSCC;
• arising in a person with immune suppression;
• growing around a nerve; or
• likely to require a flap or graft after removal.

Randomized evidence in recurrent facial BCC

In the landmark 10-year randomized facial-BCC trial, recurrent tumors came back in 3.9% after Mohs compared with 13.5% after standard excision.¹⁰

A 2024 systematic review and meta-analysis likewise found lower recurrence with micrographic surgery than conventional excision across included BCC studies.¹¹ The randomized recurrent-tumor result remains the cleanest long-term comparison, but the broader evidence points in the same direction.

What the recurrent facial BCC trial means

For recurrent facial BCC, Mohs reduced the long-term recurrence rate by roughly two-thirds relative to standard excision in this trial. The practical lesson is decisive: when a facial cancer has already returned, precise complete margin mapping matters.

Higher-risk squamous cell carcinoma

In a 12-site observational cohort of 2,752 NCCN very-high-risk cSCCs, complete margin assessment with Mohs/PDEMA was associated with lower three-year local recurrence, nodal metastasis, distant metastasis, and disease-specific death than vertical-section excision.²⁵ Separate high-risk Mohs cohorts and contemporary cSCC guidance reinforce the importance of complete margin assessment and risk-directed management.^2,5,12,30,31

What the very-high-risk cSCC cohort means

This was not a randomized trial, but every measured cancer outcome favored the complete-margin group. For very-high-risk cSCC, the evidence supports treating margin control as part of oncologic strategy, not merely cosmetic precision.

Melanoma and margin-controlled surgery

Wide local excision remains excellent for most invasive melanoma. Mohs or staged margin control can be especially compelling for lentigo maligna, large or poorly defined melanoma in situ, acral disease, and selected early invasive tumors in constrained sites when melanoma-specific pathology and immunostains are available and the central debulking specimen is analyzed with permanent sections to provide complete staging information.^3,6,26–29

In a long-term cohort of 662 melanomas in situ, recurrence was 1.8% after Mohs and 5.7% after wide local excision.²⁶ In a large registry study of invasive head-and-neck melanoma, five-year disease-specific survival was 92% after Mohs and 82% after wide local excision.²⁸

What the melanoma margin evidence means

The modern evidence does not support dismissing melanoma Mohs as a cosmetic compromise. In properly selected patients and experienced programs, margin-controlled surgery provides excellent local control, tissue preservation, and oncologically favorable outcomes. The detailed melanoma guide explains where it fits and where standard excision remains appropriate.

Standard Excision

Standard excision is an excellent treatment for many primary, well-defined BCCs and cSCCs. It also remains the standard local operation for most invasive melanomas when guideline margins can be obtained with acceptable function and reconstruction.^1–6

It is often a strong choice when:

• the tumor is primary and well defined;
• the site can safely accommodate the planned margin;
• pathology does not show an aggressive pattern;
• recurrence risk is lower;
• immediate complete mapped margin information would not change the repair; and
• the melanoma pathway requires a guideline-defined wide excision and stage-specific planning.

The limitation is margin sampling. That may be entirely reasonable for a straightforward low-risk tumor. It becomes more consequential when the border is unpredictable or a major repair could rearrange tissue before residual cancer is localized.^8,9

Curettage and Electrodesiccation

Curettage and electrodesiccation, often called ED&C, uses a curette to remove friable tumor and electrodesiccation to treat the base. It can produce durable control in carefully selected, primary, well-defined lower-risk keratinocyte cancers.^14–16

It does not provide an oriented complete margin specimen. It is therefore a poor fit for recurrent, aggressive, deeply invasive, poorly defined, or high-stakes tumors.

What this means

ED&C is not “bad surgery.” It is a lower-information treatment that works best when the cancer is sufficiently predictable that complete mapped margin information is unlikely to change the outcome.

Topical Therapy and Other Surface Treatments

Imiquimod or 5-fluorouracil can treat selected superficial BCC or SCC in situ. These medicines create an inflammatory reaction over days or weeks and require adherence.^17,18

In a randomized superficial-BCC trial, five-year tumor-free survival was:

These treatments can be useful when the diagnosis and depth fit. The numbers do not apply to invasive, recurrent, aggressive, or high-risk tumors.¹⁷

What this means

The word “cream” does not mean ineffective, but it also does not mean equivalent to surgery. Topical treatment trades microscopic margin certainty and generally stronger surgical control for lower procedural burden in a carefully selected superficial cancer.

Radiation Therapy

Radiation treats the tumor and a surrounding field in place over multiple sessions. It is guideline-supported when surgery is not feasible or is declined after informed counseling and as postoperative treatment in selected high-risk settings.¹⁹

Radiation does not provide an excised microscopic margin specimen. Acute reactions and later pigment, vascular, texture, atrophy, fibrosis, or hair changes can occur. Modern superficial-radiation cohorts report high local control in selected populations, but direct high-quality comparison with Mohs across Mohs-eligible higher-risk tumors is still missing.^19–22

What this means

Radiation is a legitimate treatment, not “surgery without a scar.” It substitutes a treated field and follow-up response assessment for surgical removal and microscopic margin confirmation. That trade can be sensible when surgery is not a good fit; it is not automatically an equal substitute for Mohs in a margin-critical tumor.

Systemic Therapy and Multidisciplinary Care

Drug treatment is not usually needed for routine local BCC or cSCC. It becomes relevant when disease is locally advanced, cannot be managed reasonably with local treatment, involves lymph nodes or distant sites, or has selected high-risk features.^5,6,23,24

Melanoma systemic treatment is stage driven. Immunotherapy or targeted therapy may be used after surgery, before surgery in selected resectable stage III disease, or for advanced disease. These decisions belong in a coordinated melanoma pathway rather than a generic local-treatment menu.⁶

When Treatment May Be Deferred

Occasionally, immediate treatment may not be the best choice. Observation can be reasonable when:

• the tumor is expected to grow slowly;
• competing health risks or limited life expectancy outweigh the likely benefit;
• treatment burden is disproportionate;
• the patient understands the tradeoff; and
• follow-up is reliable.¹³

This is not the same as ignoring cancer. A defensible observation plan states why waiting is reasonable, what will be monitored, and what change will trigger treatment.

A Practical Comparison

A Diagnosis-First Decision Map

Questions to Ask Before Choosing Treatment

1. What exact diagnosis and risk category am I treating?
2. Is the tumor in situ or invasive?
3. How will the peripheral and deep margins be evaluated?
4. Which treatment has the strongest control evidence for this tumor and site?
5. What information will we have before reconstruction begins?
6. What happens if the first treatment fails?
7. How many visits and what healing burden should I expect?
8. Is my immune status or another health condition changing the recommendation?
9. Would a fellowship-trained Mohs surgeon or multidisciplinary consultation add value?
10. Which focused Skin Trust guide explains my diagnosis in detail?

Next Steps in the Patient Journey

Continue to the diagnosis-specific guide or focused comparison that matches your decision.